Uniphar PLC
28 July 2026
Uniphar plc
Half-Year Trading Update and Notice of Results
Dublin, London | 28 July 2026: Uniphar plc (the "Group" or "Uniphar"), an international diversified healthcare services business, today announces the following unaudited trading update for the six months ended 30 June 2026.
The business achieved ca. 11% adjusted EPS growth in the first half of 2026, in line with the Group's expectations, driven by a strong trading performance with ca. 7% organic gross profit growth.
Divisional performance:
· Uniphar Pharma delivered high single-digit organic gross profit growth during the period and is on track to deliver double-digit organic gross profit growth for the full year.
· Uniphar Medtech achieved high single-digit organic gross profit growth during the half and remains on track to deliver high single-digit organic gross profit growth for the full year.
· Uniphar Supply Chain & Retail delivered mid-single-digit organic gross profit growth during the half and is expected to deliver mid-single-digit organic gross profit growth for the full year.
The Group continues to maintain a strong liquidity position, with Net Bank Debt/EBITDA of 2.4x at the end of June 2026, reflecting the expected unwind of previously communicated favourable working capital movements.
Outlook and strategic update
Uniphar enters the second half of the year with strong trading momentum across the Group, and underlying trading expectations for the year remain unchanged.
The new high-tech distribution facility in Ireland will now go live in February 2027, with a phased roll-out during H1 2027. This extended timeline allows for additional end-to-end testing and minimises execution risk during the Group's seasonal peak trading period in the fourth quarter. As a result, the project will require incremental capital expenditure of approximately €20m.
The revised timeline will defer associated depreciation and amortisation charges, resulting in a benefit to FY 2026 adjusted EPS expectations.
M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.
Ger Rabbette, Uniphar Group Chief Executive Officer said:
"Uniphar has delivered a strong first half, with continued organic gross profit growth across the Group. Trading continues to be robust and the business is developing in line with our expectations. We expect to sustain this progress into the second half and remain on track to meet our growth objectives for each of our three divisions for the full year. We also remain confident in our ability to reach our €200m EBITDA target by 2028, with at least 80% of growth expected to be organic."
Notice of Results
The Group expects to publish its interim results for the six months ended 30 June 2026 at 07:00 am (BST) on 8 September 2026.
A conference call for analysts and investors will be held at 9.00 am (BST) on 8 September 2026 to discuss the Group's interim results. Analysts and investors who wish to participate should visit www.uniphar.ie to register.
The Company's interim results press release and presentation will also be available on the website at 07.00 am (BST) on 8 September 2026 at www.uniphar.ie.
--- ENDS ---
Contact details
|
Uniphar Group |
Tel: +353 (0) 1 428 7777 |
|
Allan Smylie, Head of Strategy and IR |
|
|
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor) |
Tel: +353 (0) 1 679 6363 |
|
Daragh O'Reilly Niall Gilchrist Ivan Murphy |
|
|
RBC Capital Markets (Joint Corporate Broker)
|
Tel: +44 (0) 20 7653 4000 |
|
Jamil Miah Daniel Saveski |
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
|
Tel: +44 (0) 20 7710 7600 |
|
Matt Blawat Ben Maddison Francis North |
|
|
Q4 PR |
Tel: +353 (0) 1 475 1444 |
|
Iarla Mongey, Public Relations Advisor to Uniphar Group |
|
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.